Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "buy" rating reiterated by analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They currently have a $36.00 price target on the biopharmaceutical company's stock. D. Boral Capital's target price would indicate a potential upside of 274.61% from the stock's current price.

Other research analysts have also issued reports about the company. Rodman & Renshaw started coverage on Omeros in a research report on Thursday, November 14th. They issued a "buy" rating and a $9.00 price objective for the company. StockNews.com upgraded Omeros from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Friday, January 17th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Omeros in a research report on Thursday, November 14th. Finally, RODMAN&RENSHAW upgraded shares of Omeros to a "strong-buy" rating in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Omeros has a consensus rating of "Moderate Buy" and an average price target of $22.50.

Omeros Price Performance

Shares of OMER traded up $0.36 during trading hours on Thursday, hitting $9.61. 724,692 shares of the stock were exchanged, compared to its average volume of 507,703. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The business has a 50-day moving average of $9.25 and a 200-day moving average of $6.69. The firm has a market capitalization of $556.90 million, a P/E ratio of -4.16 and a beta of 1.98.

Institutional Investors Weigh In On Omeros

Several large investors have recently modified their holdings of the stock. Truvestments Capital LLC lifted its stake in Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 1,972 shares during the period. Quantbot Technologies LP purchased a new stake in Omeros in the 4th quarter worth about $46,000. BNP Paribas Financial Markets raised its stake in Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 7,016 shares during the period. Finally, Picton Mahoney Asset Management lifted its holdings in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 4,404 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.